Stabilisation of vaccines using trehalose (Q-T4) technology.
Efforts directed towards overcoming the problems of vaccine stability must take cost into consideration. One effective approach is the use of a simple stabilization technology applicable, in principle, to every type of vaccine candidate. Following the lead of Nature, the results in this paper show how such techniques based on trehalose have the potential to transform contemporary vaccine manufacture. The possibilities of novel delivery formats and vaccine combinations, currently not feasible, may now also be realised.
Gribbon
E M
EM
Quadrant Holdings Cambridge Limited, Vaccine Division, England.
Sen
S D
SD
Roser
B J
BJ
Kampinga
J
J
D000276:Adjuvants, Immunologic; D000536:Aluminum Hydroxide; D000942:Antigens, Bacterial / Q000737:chemistry / Q000187:drug effects / Q000276:immunology; D004168:Diphtheria Toxoid / Q000737:chemistry* / Q000191:economics / Q000592:standards; D004355:Drug Stability; D004356:Drug Storage; D005612:Freeze Drying; D005947:Glucose / Q000494:pharmacology; D011310:Preservatives, Pharmaceutical / Q000494:pharmacology*; D013395:Sucrose / Q000494:pharmacology; D013745:Tetanus Toxoid / Q000737:chemistry* / Q000191:economics / Q000592:standards; D014199:Trehalose / Q000494:pharmacology*
D000276:Adjuvants, Immunologic; D000942:Antigens, Bacterial; D004168:Diphtheria Toxoid; D011310:Preservatives, Pharmaceutical; D013745:Tetanus Toxoid; D013395:Sucrose; D000536:Aluminum Hydroxide; D014199:Trehalose; D005947:Glucose